AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17545843
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2 on days 1 and 8, every 21 days for three cycles, followed by Docetaxel 35 mg/m2 on days 1, 8, and 15, every 28 days for three cycles (S0027)
Trial: 17545843
Drug: Docetaxel 30
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 30 mg/m2 on days 1, 8, and 15, every 28 days, or 75 mg/m2 every 21 days (LUN 6)
Trial: 17524571
Drug: 7 x
RxNorm normalized name: TachoSil 3.7 X 1.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 x 5.2 Gy High-Dose-Rate Brachytherapy (HDR-BT)
Trial: 11526363
Drug: Sibutramine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 20 mg once daily for 24 weeks
Trial: 8322247
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of terbutaline nebuliser solution
Trial: 31917054
Drug: Early-stage periarticular
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-stage periarticular injection (injection just before arthrotomy)
Trial: 31917054
Drug: Late-stage periarticular
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-stage periarticular injection (placebo before arthrotomy, injection after implantation)
Trial: 31160295
Drug: Oral (PO)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (PO) methotrexate (MTX)
Trial: 26079800
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal catheter (3-day ropivacaine 0.2% infusion)
Trial: 26079800
Drug: Femoral catheter
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral catheter (3-day ropivacaine 0.2% infusion)
Trial: 21121960
Drug: modSLA implants
RxNorm normalized name: Mosla cavaleriei whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modSLA implants
Trial: 19216016
Drug: Pentoxifylline, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline, 400 mg twice daily
Trial: 15111342
Drug: Infusional 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusional 5-FU 200 mg/m² daily continuous infusion for 18 weeks with epirubicin 60 mg/m² and cisplatin 60 mg/m² (infusional ECisF)
Trial: 15111342
Drug: Conventional bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional bolus doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (AC)
Trial: 28254231
Drug: Cervical ripening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical ripening balloon (CRB) group with double‐balloon catheter (COOK CRB), inflated with 30‐80 mL of normal saline for 12 hours
Trial: 28254231
Drug: Non-CRB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-CRB group (vaginal and oral misoprostol alone)
Trial: 22946635
Drug: Yogurt containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt containing Lactobacillus rhamnosus GG (LGG) and fructooligosaccharide (FOS) Actilight(®) administered daily for 4 weeks
Trial: 19258143
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 1% lidocaine
Trial: 21658884
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 0.9% NaCl
Trial: 19366275
Drug: Ivabradine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 10 mg twice daily for 7 days, followed by 15 mg twice daily if no visual symptoms reported
Trial: 15823773
Drug: Sibutramine mesylate
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine mesylate hemihydrate (17.3 mg oral dose)
Trial: 15823773
Drug: Sibutramine hydrochloride
RxNorm normalized name: Sibutramine Hydrochloride
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine hydrochloride monohydrate (15 mg oral dose)
Trial: 11700399
Drug: rTFPI at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTFPI at 0.025 mg/kg/hr
Trial: 11700399
Drug: rTFPI at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTFPI at 0.05 mg/kg/hr
Trial: 11700399
Drug: rTFPI (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTFPI (both doses)
Trial: 9404177
Drug: Enflurane administered
RxNorm normalized name: Enflurane
DrugBank: Enflurane (DB00228)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enflurane administered via a laryngeal mask airway (LMA)
Trial: 9404177
Drug: Enflurane anaesthesia
RxNorm normalized name: Enflurane
DrugBank: Enflurane (DB00228)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enflurane anaesthesia administered using a face mask
Trial: 2961307
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration of 5'-DFUR (800 mg/m2/day)
Trial: 2961307
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of 5'-DFUR (1,400 mg/m2/day for 4 days followed by 3 days off)
Trial: 22759198
Drug: Apixaban 0.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 0.5-2.5 mg as solution or 5-50 mg as tablets
Trial: 24725442
Drug: Apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 10 mg
Trial: 14719426
Drug: Adenosine 10
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine 10 mg in 5 ml saline with prilocaine 1% 10 ml and lignocaine 2% 20 ml with adrenaline 1:200,000 (Group 1)
Trial: 14719426
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml saline (placebo control) with prilocaine 1% 10 ml and lignocaine 2% 20 ml with adrenaline 1:200,000 (Group 2)
Trial: 8197031
Drug: Hydrocodone bitartrate
RxNorm normalized name: Hydrocodone Bitartrate
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hydrocodone bitartrate 7.5 mg with acetaminophen 500 mg
Trial: 8197031
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate 30 mg with acetaminophen 300 mg
Trial: 3147522
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 mg twice daily for 1 week)
Trial: 3147522
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice daily for 1 week)
Trial: 28130435
Drug: GnRH-agonist protocol
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH-agonist protocol
Trial: 31346609
Drug: Ongoing injection
RxNorm normalized name: Ongo-Fin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing injection drug use (IDU)
Trial: 31329983
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution (PS)
Trial: 23354314
Drug: Mild water‐filtered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild water‐filtered near infrared whole body hyperthermia twice a week
Trial: 18469732
Drug: Probiotic Escherichia
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Escherichia coli Nissle 1917 (EcN) suspension (1-3 mL daily for 21 days)
Trial: 16556690
Drug: Inhaled human
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled human insulin (INH)
Trial: 12545256
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Open craniotomy and Stereotactic biopsy)
Trial: 8727434
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine infusion (2 micrograms.kg-1.min-1) during 2-hour periods
Trial: 8727434
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine infusion (2 micrograms.kg-1.min-1) after 48 hours
Trial: 8727434
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine infusion (2 micrograms.kg-1.min-1)
Trial: 1888820
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg fluconazole daily for 14‐28 days
Trial: 1888820
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg fluconazole weekly for 6 months
Trial: 1888820
Drug: Placebo weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo weekly for 6 months
Trial: 6384850
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g, 12 doses)
Trial: 3532966
Drug: Cyclosporin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (10 mg/kg daily for two months)
Trial: 29231607
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of regular acupuncture and contralateral needling technique at distal acupoints
Trial: 23550665
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy Japanese version (CST-J), 14 sessions, twice a week for 7 weeks
Trial: 23550665
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy Japanese version (CST-J)
Trial: 17978857
Drug: Intraoperative single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative single bolus rabbit ATG in a dose of 9 mg/kg
Trial: 16857836
Drug: FeSO4 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeSO4 (3 mg vs 20 mg)
Trial: 9268948
Drug: MVP (platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVP (platinum-based chemotherapy)
Trial: 9268948
Drug: MACC (non-platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MACC (non-platinum-based combination chemotherapy)
Trial: 8274720
Drug: vitamin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin therapy
Trial: 3544860
Drug: Pulsatile glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulsatile glucagon infusion (812.5 ng X min‐1, 2/11 min on/off)
Trial: 3544860
Drug: Continuous glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous glucagon infusion (125 ng X min‐1)
Trial: 3544860
Drug: Pulsatile glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulsatile glucagon infusion
Trial: 28478984
Drug: Walking Bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking Bleaching (WB) technique; sodium perborate and 20% hydrogen peroxide applied in pulp chambers, replaced weekly for 4 weeks
Trial: 26677667
Drug: ZHU's Tiaojing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZHU's Tiaojing Cuyun Recipe (TCR), one dose per day for 2 courses (3 menstrual cycles each).
Trial: 26677667
Drug: Clomifene Citrate
RxNorm normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomifene Citrate (CC), 50 mg per day for 2 courses (3 menstrual cycles each).
Trial: 22384541
Drug: Clomifene Citrate
RxNorm normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomifene Citrate (CC)
Trial: 22975216
Drug: Peg‐IFN 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN 100 μg SC once weekly for 36 months
Trial: 22975216
Drug: IFN 3
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN 3 MU SC three times weekly for 18 months
Trial: 1385295
Drug: Acyclovir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (400 mg twice daily)
Trial: 20833591
Drug: Cilostazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100 mg twice daily)
Trial: 17139367
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clopidogrel and aspirin
Trial: 17139367
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clopidogrel and cilostazol
Trial: 17139367
Drug: Triple-drug combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug combination (aspirin, clopidogrel, cilostazol)
Trial: 11112089
Drug: Atorvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin with evening meals
Trial: 11112089
Drug: Atorvastatin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin after meals
Trial: 3084617
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (DPA) 400 mg orally
Trial: 16980907
Drug: Carraguard (carrageenan-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carraguard (carrageenan-derived microbicide gel)
Trial: 16980907
Drug: Placebo (methylcellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (methylcellulose gel)
Trial: 12738504
Drug: Soy-derived isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-derived isoflavones (72 mg daily)
Trial: 9285659
Drug: Low-dose amiodarone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amiodarone (10 mg/kg/day for a minimum of 14 days, followed by 200 mg/day for maintenance)
Trial: 9285659
Drug: Conventional antiarrhythmic
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antiarrhythmic drug therapy (sotalol or propafenone)
Trial: 9285659
Drug: Conventional antiarrhythmic
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antiarrhythmic drug therapy
Trial: 8222496
Drug: L-365,260 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-365,260 50 mg
Trial: 8222496
Drug: L-365,260 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-365,260 (all doses combined)
Trial: 3534862
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg two times a day) for 8 weeks
Trial: 3534862
Drug: Chlorthalidone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (25 mg/day) for 8 weeks
Trial: 25023977
Drug: Cinnarizine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine (1.5 mg/kg/day for children <30 kg or 50 mg for children >30 kg, administered at bedtime)
Trial: 18004920
Drug: Maxillary canines
RxNorm normalized name: Artemisia capillaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary canines (treatment group)
Trial: 18004920
Drug: Maxillary microscrew
RxNorm normalized name: Artemisia capillaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary microscrew implants (implant group)
Trial: 16408384
Drug: Formula supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula supplemented with 0.4 g/100ml oligosaccharides (9 to 1 mixture of galacto- and fructooligosaccharides)
Trial: 9931077
Drug: Nifedipine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (all formulations)
Trial: 9931077
Drug: Other active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other active drug controls
Trial: 9931077
Drug: Immediate-release nifedipine
RxNorm normalized name: nifedipine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release nifedipine
Trial: 6411792
Drug: Enteral feeding
RxNorm normalized name: enteral feeding dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral feeding (Vivonex HN) via needle catheter jejunostomy (NCJ) starting at 18 hours postoperatively, advanced to 3,000 cc/day within 72 hours.
Trial: 19039085
Drug: Individually adjusted
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually adjusted GH dose (IAD) starting at 0.035 mg/kg per day, increased to 0.067 mg/kg per day if growth prediction was <0.75 at 3 months
Trial: 19039085
Drug: Fixed high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed high GH dose (FHD) at 0.067 mg/kg per day throughout the study
Trial: 15126234
Drug: SSRI group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI group (paroxetine 10 mg-40 mg/day and sertraline 50 mg-150 mg/day)
Trial: 9146858
Drug: Phenytoin (PHT)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin (PHT) 100 mg single oral dose
Trial: 3622539
Drug: Nalbuphine (≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (≤ 20 mg)
Trial: 3622539
Drug: Diamorphine (≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine (≤ 5 mg)
Trial: 25045825
Drug: MF59®-adjuvanted trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59®-adjuvanted trivalent influenza vaccine (aTIV)
Trial: 25045825
Drug: Non-adjuvanted seasonal
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted seasonal influenza vaccine (TIV)
Trial: 16396699
Drug: Amtolmetin guacyl
RxNorm normalized name: Amtolmetin guacil
DrugBank: Amtolmetin guacil (DB16088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amtolmetin guacyl (AMG) 600 mg twice daily
Trial: 12573744
Drug: Continuous hyperfractionated
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperfractionated accelerated radiotherapy (V-CHART) with mitomycin C (20 mg/m² on day 5)
Trial: 8916639
Drug: Psychodynamic‐interpersonal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic‐interpersonal therapy (16 sessions)
Trial: 8916639
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy (16 sessions)
Trial: 8916639
Drug: Psychodynamic‐interpersonal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic‐interpersonal therapy (8 sessions)
Trial: 8916639
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy (8 sessions)
Trial: 8916639
Drug: CPP clients
RxNorm normalized name: CPPD
DrugBank: N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine (DB14196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP clients (combined treatment approaches)
Trial: 8916639
Drug: SPP2 clients
RxNorm normalized name: OCTINOXATE 0.0664 g in 1 g / OXYBENZONE 0.0151 g in 1 g TOPICAL LIPSTICK [ESIKA HYDRACOLOR 2 IN 1 SPF 25 (PIMIENTA CALIENTE) - BROWN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP2 clients (combined treatment approaches)
Trial: 30763661
Drug: 18 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 Gy hyperfractionated radiation therapy (RT) given in twice-daily fractions of 1.5 Gy each
Trial: 30095381
Drug: Vancomycin (VCM)
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin (VCM) 1 g
Trial: 30095381
Drug: Ampicillin (AMP)
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin (AMP) 1 g
Trial: 22183220
Drug: Porcine subintestinal
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine subintestinal submucosal graft augmentation
Trial: 12472197
Drug: Twenty-four hour
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty-four hour urinary albumin excretion rates (UAER)
Trial: 9531874
Drug: IM triptorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM triptorelin (3.75 mg)
Trial: 9531874
Drug: SC triptorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC triptorelin (3.75 mg)
Trial: 2487529
Drug: Indapamide (IND)
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide (IND) 2.5 mg
Trial: 2487529
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg + Amiloride 2.5 mg (HCTZ + A)
Trial: 26989888
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg PEX168
Trial: 26989888
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg PEX168
Trial: 26296497
Drug: A/H5N2 live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/H5N2 live attenuated influenza vaccine
Trial: 19929597
Drug: ezetimibe/simvastatin (E/S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin (E/S) combination therapy
Trial: 17016527
Drug: Standardized IOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized IOP treatment protocol (ranging from topical monotherapy to filtration surgery)